Urapidil
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Urapidil is a combination adrenergic antagonist and serotonin agonist given orally for the treatment of essential hypertension and intravenously in hypertensive emergencies.
- Generic Name
- Urapidil
- DrugBank Accession Number
- DB12661
- Background
Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 387.484
Monoisotopic: 387.227039814 - Chemical Formula
- C20H29N5O3
- Synonyms
- Urapidil
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of High blood pressure (hypertension) •••••••••••• Treatment of Hypertensive emergency •••••••••••• •••••••••• •••••••••• ••••••••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism A5-hydroxytryptamine receptor 1A agonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Urapidil. Abaloparatide Abaloparatide may increase the hypotensive activities of Urapidil. Acebutolol Acebutolol may increase the orthostatic hypotensive activities of Urapidil. Aceclofenac The therapeutic efficacy of Urapidil can be decreased when used in combination with Aceclofenac. Acemetacin The therapeutic efficacy of Urapidil can be decreased when used in combination with Acemetacin. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- C02CA06 — Urapidil
- Drug Categories
- Adrenergic Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Agents that produce hypertension
- Antiadrenergic Agents, Peripherally Acting
- Antidepressive Agents
- Antihypertensive Agents
- Cardiovascular Agents
- Central Nervous System Depressants
- Neurotransmitter Agents
- Peripheral alpha-1 blockers
- Serotonin Agents
- Serotonin Receptor Agonists
- Vasodilating Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- Phenylpiperazines
- Alternative Parents
- N-arylpiperazines / Aminophenyl ethers / Methoxyanilines / Anisoles / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / N-alkylpiperazines / Aminopyrimidines and derivatives / Alkyl aryl ethers show 12 more
- Substituents
- Alkyl aryl ether / Amine / Aminophenyl ether / Aminopyrimidine / Aniline or substituted anilines / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Dialkylarylamine show 28 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- A78GF17HJS
- CAS number
- 34661-75-1
- InChI Key
- ICMGLRUYEQNHPF-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
- IUPAC Name
- 6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
- SMILES
- COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1
References
- General References
- External Links
- PubChem Compound
- 5639
- PubChem Substance
- 347828865
- ChemSpider
- 5437
- BindingDB
- 50237617
- 39230
- ChEBI
- 32278
- ChEMBL
- CHEMBL279229
- ZINC
- ZINC000001544805
- Wikipedia
- Urapidil
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Diagnostic General Surgery 1 somestatus stop reason just information to hide Not Available Completed Treatment Aortic Aneurysms / Hemodynamic Stability / Post Operative Nausea and Vomiting (PONV) / Postoperative pain 1 somestatus stop reason just information to hide Not Available Completed Treatment Cerebral Hemorrhage / Intracranial Hemorrhages / Stroke 1 somestatus stop reason just information to hide Not Available Completed Treatment Scheduled Laparoscopic Surgery 1 somestatus stop reason just information to hide Not Available Not Yet Recruiting Not Available Intracerebral Hemorrhage, Hypertensive 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 30 MG Capsule Oral 60 MG Injection, solution Intravenous Capsule, extended release Oral 30 mg/1 Capsule, extended release Oral 30 MG Injection, solution Intravenous 50 mg/10ml Capsule, extended release Oral 60 mg/1 Capsule, extended release Oral 90 mg/1 Capsule Oral Injection, solution Intravenous 25 mg/5ml Capsule, extended release Oral Injection, solution Parenteral Injection, solution, concentrate Intravenous Solution Intravenous 5 mg Injection, solution 25 MG Injection, solution 50 MG Injection, solution Parenteral 25 MG Injection, solution Parenteral 50 MG Injection, solution, concentrate Intravenous 100 MG Capsule, extended release Oral 60 MG Capsule, extended release Oral 90 MG Injection Intravenous Injection, solution Intravenous; Parenteral 100 MG/20ML Injection, solution Intravenous; Parenteral 25 MG/5ML Injection, solution Intravenous; Parenteral 50 MG/10ML - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.541 mg/mL ALOGPS logP 1.69 ALOGPS logP 1.18 Chemaxon logS -2.9 ALOGPS pKa (Strongest Basic) 8.11 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 68.36 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 119.37 m3·mol-1 Chemaxon Polarizability 43.07 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 185.80992 predictedDeepCCS 1.0 (2019) [M+H]+ 188.72145 predictedDeepCCS 1.0 (2019) [M+Na]+ 196.76047 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. Details5-hydroxytryptamine receptor 1A
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:22957663, PubMed:3138543, PubMed:33762731, PubMed:37935376, PubMed:37935377, PubMed:8138923, PubMed:8393041). Also functions as a receptor for various drugs and psychoactive substances (PubMed:22957663, PubMed:3138543, PubMed:33762731, PubMed:38552625, PubMed:8138923, PubMed:8393041). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (PubMed:22957663, PubMed:3138543, PubMed:33762731, PubMed:8138923, PubMed:8393041). HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores (PubMed:33762731, PubMed:35610220). Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes (PubMed:18476671, PubMed:20363322, PubMed:20945968). Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism (PubMed:18476671, PubMed:20363322, PubMed:20945968). Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior (PubMed:18476671, PubMed:20363322, PubMed:20945968). Plays a role in the response to anxiogenic stimuli (PubMed:18476671, PubMed:20363322, PubMed:20945968)
- Specific Function
- G protein-coupled serotonin receptor activity
- Gene Name
- HTR1A
- Uniprot ID
- P08908
- Uniprot Name
- 5-hydroxytryptamine receptor 1A
- Molecular Weight
- 46106.335 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at October 20, 2016 23:31 / Updated at August 26, 2024 19:24